Journal
VASCULAR MEDICINE
Volume -, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1358863X231206778
Keywords
anticoagulation; bleeding events; factor XI; thromboprophylaxis; thrombosis; venous thromboembolism (VTE)
Categories
Ask authors/readers for more resources
This review summarizes the key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and describes the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.
During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available